Cardio Cases · adult-congenital-heart-disease
Coarctation of the aorta in adults — practice case: recoarctation before pregnancy
Practice case: a woman with childhood patch repair of coarctation, hypertension and a raised limb gradient who plans pregnancy; re-coarctation and repair-site complications, cross-sectional imaging and ambulatory blood pressure, ESC 2024 and ACC/AHA 2025 repair rows, pregnancy risk (ACC/AHA 2025 Table 10, ESC 2025 Table 12) and follow-up after stenting.
On this page
Study tools
Target exams
- EECC
- ABIM Cardiovascular Disease Certification
Presentation
Practice case (not a real patient). A 30-year-old woman had coarctation of the aorta repaired with a patch in childhood and has not been seen in a cardiology clinic for years. She plans a pregnancy next year.[1][7] Her right-arm blood pressure is raised, the systolic difference between her right arm and leg is 30 mmHg, and her femoral pulses are delayed. She has no cardiac symptoms.[1]
Step 1 — What is going on?
Discussion:
- ESC 2020: an increased systolic gradient (≥20 mmHg) between upper and lower extremities indicates re-coarctation and warrants invasive assessment for confirmation and treatment; radiofemoral pulse delay also indicates significant coarctation.[1]
- Patch repairs are at particular risk of repair-site aneurysms (ESC 2020), and ACC/AHA 2025 lists re-coarctation, aneurysms or pseudoaneurysms at the repair site, and dissection among the vascular complications of repaired coarctation.[1][2]
- Hypertension at rest or during exercise is common even after successful treatment, and recurring or residual coarctation may induce or aggravate it (ESC 2020).[1]
Step 2 — Investigations
Discussion:
- ACC/AHA 2025: in adults with repaired coarctation, periodic cross-sectional imaging is recommended to screen for recurrent coarctation, aortic root or ascending aneurysms and vascular complications of repair (COR 1, LOE B-NR); CMR is preferred because it avoids radiation.[2]
- ESC 2020: CMR and CCT depict the site, extent and degree of narrowing, the arch and head and neck vessels and collaterals, and detect aneurysms, false aneurysms, restenosis or residual stenosis.[1]
- Right-arm ambulatory blood pressure should be considered for the diagnosis of hypertension (ESC 2020 table footnote); ACC/AHA 2025 calls ambulatory measurement reasonable to diagnose hypertension and monitor treatment (COR 2a, LOE B-NR).[1][2]
- Echocardiography shows LV function and hypertrophy and associated abnormalities (ESC 2020); a bicuspid valve should be sought, since ACC/AHA 2022 says it coexists in at least 50% of cases.[1][4]
CMR shows a severe recoarctation at the repair site without an aneurysm, and catheterisation confirms a peak-to-peak gradient of 32 mmHg; stenting is technically feasible.[2][1]
Step 3 — Treatment before pregnancy
Discussion:
- ESC 2024: coarctation or re-coarctation repair is indicated in patients with hypertension with an increased non-invasive gradient confirmed with invasive measurement (peak-to-peak >20 mmHg), with a preference for stenting when technically feasible (Class I, Level C).[3]
- ACC/AHA 2025: surgical or transcatheter stent therapy is recommended for anatomically and hemodynamically significant native or repaired coarctation to prevent irreversible LV dysfunction from chronic pressure overload (COR 1, LOE B-NR).[2]
- Pregnancy: ACC/AHA 2025 Table 10 lists severe native coarctation or recoarctation as significantly high risk for maternal complications, and ESC 2025 Table 12 advises pre-pregnancy CMR and treatment of residual lesions.[2][7]
- ACC/AHA 2022: after a previous open repair, an endovascular approach to recoarctation, aneurysm or pseudoaneurysm avoids reoperation, assuming adequate iliofemoral access and no involvement of the supra-aortic trunks.[4]
Step 4 — Pregnancy and follow-up
Discussion:
- ESC 2025 Table 12 for coarctation: close blood pressure monitoring, also early post-partum; treat hypertension; vaginal delivery preferred unless aneurysm, heart failure or severe hypertension.[7]
- It lists a higher complication risk with residual obstruction (gradient >20 mmHg, aortic lumen <12 mm), clinical signs of heart failure, LVEF <40% or NYHA class >1, a higher miscarriage rate, and pre-term birth and low birth weight in 9%.[7]
- After the stent, CT angiography rather than CMR should be used for imaging because of stent artefacts on CMR (ACC/AHA 2025), and ESC 2024 recommends lifelong follow-up in native or repaired coarctation, including regular CCT/CMR of the aorta every 3–5 years adapted to clinical status and previous imaging findings (Class I, Level B).[2][3]
- If hypertension persists without hemodynamically significant coarctation, GDMT is recommended to maintain controlled resting and ambulatory blood pressure (ACC/AHA 2025, COR 1, LOE B-NR).[2]
Learning points
- A raised upper-to-lower limb gradient after repair points to re-coarctation and needs invasive confirmation (ESC 2020).[1]
- Severe recoarctation is high risk in pregnancy, so the residual lesion is treated before pregnancy (ACC/AHA 2025 Table 10; ESC 2025 Table 12).[2][7]
- After a stent, image with CT angiography (ACC/AHA 2025).[2]
References5ShowHide
- [1]Baumgartner H, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J, 2021.PMID 32860028
- [2]Gurvitz M, et al. 2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2026.PMID 41411375
- [3]Mazzolai L, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J, 2024.PMID 39210722
- [4]Isselbacher EM, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation, 2022.PMID 36322642
- [7]De Backer J, et al. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. Eur Heart J, 2025.PMID 40878294